During the past decade, Hôpital Pellegrin-Enfants conducted 12 clinical trials. In the 10-year time frame, 12 clinical trials started and 9 clinical trials were completed, i.e. on average, 75% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 6 clinical trials were completed. i.e. 300% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hôpital Pellegrin-Enfants" #1 sponsor was "Allergan" with 2 trials, followed by "Institut de Recherches Internationales Servier" with 2 trials sponsored, "Amzell" with 1 trials sponsored, "Ascendis Pharma A/S" with 1 trials sponsored and "Baxalta now part of Shire" with 1 trials sponsored. Other sponsors include 8 different institutions and companies that sponsored additional 18 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hôpital Pellegrin-Enfants" #1 collaborator was "ADIR, a Servier Group company" with 2 trials as a collaborator, "Baxalta Innovations GmbH, now part of Shire" with 1 trials as a collaborator, "Bicetre Hospital" with 1 trials as a collaborator, "Gustave Roussy, Cancer Campus, Grand Paris" with 1 trials as a collaborator and "Hospices Civils de Lyon" with 1 trials as a collaborator. Other collaborators include 3 different institutions and companies that were collaborators in the rest 13 trials.

According to Clinical.Site data, the most researched conditions in "Hôpital Pellegrin-Enfants" are "Autism Spectrum Disorder (ASD)" (2 trials), "Urinary Incontinence" (2 trials), "ADHD Inattention or Mixed Type" (1 trials), "Acute Lymphoblastic Leukemia, in Relapse" (1 trials) and "Arthritis, Juvenile Rheumatoid" (1 trials). Many other conditions were trialed in "Hôpital Pellegrin-Enfants" in a lesser frequency.

Most popular intervention types in "Hôpital Pellegrin-Enfants" are "Drug" (14 trials), "Biological" (4 trials), "Device" (1 trials), "Dietary Supplement" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "OnabotulinumtoxinA" (2 trials), "PLACEBO" (2 trials), "Placebo" (2 trials), "6-mercaptopurine" (1 trials) and "ACP-001" (1 trials). Other intervention names were less common.

The vast majority of trials in "Hôpital Pellegrin-Enfants" are 19 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Hôpital Pellegrin-Enfants". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 15 completed trials in Hôpital Pellegrin-Enfants, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Hôpital Pellegrin-Enfants, 1 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 11 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".